IN8BIO, INC. Files 2024 Annual Report Amendment
Ticker: INAB · Form: 10-K/A · Filed: May 7, 2025 · CIK: 1740279
| Field | Detail |
|---|---|
| Company | In8bio, Inc. (INAB) |
| Form Type | 10-K/A |
| Filed Date | May 7, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: amendment, annual-report, biotech
TL;DR
IN8BIO filed its 2024 10-K amendment, check for updates.
AI Summary
IN8BIO, INC. filed an amendment (10-K/A) on May 7, 2025, for its fiscal year ended December 31, 2024. The company, formerly known as Incysus Therapeutics, Inc., is in the biological products sector and is headquartered in New York. This filing is an annual report under the Securities Exchange Act of 1934.
Why It Matters
This amendment provides updated financial and operational information for IN8BIO, INC. for the fiscal year 2024, which is crucial for investors to assess the company's performance and outlook.
Risk Assessment
Risk Level: medium — As a company in the biological products sector, IN8BIO likely faces significant research and development risks, regulatory hurdles, and market competition.
Key Numbers
- 2024 — Fiscal Year End (The period covered by the annual report.)
- May 7, 2025 — Filing Date (The date the amendment was submitted to the SEC.)
Key Players & Entities
- IN8BIO, INC. (company) — Registrant
- Incysus Therapeutics, Inc. (company) — Former company name
- 2024 (date) — Fiscal year end
- May 7, 2025 (date) — Filing date
- New York (location) — Business address
FAQ
What specific information is being amended in this 10-K/A filing?
The provided text does not specify the exact details of the amendment, only that it is an amendment to the annual report for the fiscal year ended December 31, 2024.
When was IN8BIO, INC. formerly known as Incysus Therapeutics, Inc.?
The company changed its name from Incysus Therapeutics, Inc. on May 10, 2018.
What is IN8BIO, INC.'s primary business sector?
IN8BIO, INC. is in the BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) sector, SIC code 2836.
Where is IN8BIO, INC. headquartered?
IN8BIO, INC. is headquartered at 350 5th Avenue, Suite 5330, New York, NY 10118.
What is the SEC file number for IN8BIO, INC.?
The SEC file number for IN8BIO, INC. is 001-39692.
Filing Details
This Form 10-K/A (Form 10-K/A) was filed with the SEC on May 7, 2025 regarding IN8BIO, INC. (INAB).